Journal of Clinical Endocrinology & Metabolism, Vol 63, 960-967, Copyright © 1986 by Endocrine Society

ARTICLES

Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma

M Schlumberger, M Tubiana, F De Vathaire, C Hill, P Gardet, JP Travagli, P Fragu, J Lumbroso, B Caillou and C Parmentier

We assessed the results of treatment in 283 patients with lung or bone metastases from differentiated thyroid carcinoma who were followed for up to 40 yr (median, 44 months) after the discovery of the metastases. The survival rates from the time of discovery of the metastases were 53% at 5 yr, 38% at 10 yr, and 30% at 15 yr; 156 patients died. Multivariate analysis revealed that only 4 variables had an independent prognostic significance for survival. They were extensive metastases, older age at discovery of the metastases, absence of radioiodine uptake by the metastases, and moderately differentiated follicular cell type. The site of metastases (lung or bone) was not a prognostic factor for survival after treatment of metastatic disease. Remission was achieved in 79 patients after metastases were found. The only predictive factor for 5-yr disease-free survival after treatment of metastases was the initial extent of disease. Our results suggest that the aim of management should be to detect and treat metastases in patients with thyroid cancer as early as possible.

This article has been cited by other articles:

				R. T. Kloos Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1519 - 1525. [Abstract] [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				J. P. Lopez, J. Wang-Rodriguez, C. Chang, J. S. Chen, F. S. Pardo, J. Aguilera, and W. M. Ongkeko Gefitinib Inhibition of Drug Resistance to Doxorubicin by Inactivating ABCG2 in Thyroid Cancer Cell Lines Arch Otolaryngol Head Neck Surg, October 1, 2007; 133(10): 1022 - 1027. [Abstract] [Full Text] [PDF]

				R. M. Tuttle, R. Leboeuf, R. J. Robbins, R. Qualey, K. Pentlow, S. M. Larson, and C. Y. Chan Empiric Radioactive Iodine Dosing Regimens Frequently Exceed Maximum Tolerated Activity Levels in Elderly Patients with Thyroid Cancer J. Nucl. Med., October 1, 2006; 47(10): 1587 - 1591. [Abstract] [Full Text] [PDF]

				B Singh, R Bollmann, H Ahmadzadehfar, H J Biersack, and S Ezziddin Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine. Br. J. Radiol., September 1, 2006; 79(945): e84 - e87. [Abstract] [Full Text] [PDF]

				R. J. Robbins, Q. Wan, R. K. Grewal, R. Reibke, M. Gonen, H. W. Strauss, R. M. Tuttle, W. Drucker, and S. M. Larson Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Scanning J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 498 - 505. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				C. Ma, J. Xie, and A. Kuang Is Empiric 131I Therapy Justified for Patients with Positive Thyroglobulin and Negative 131I Whole-Body Scanning Results? J. Nucl. Med., July 1, 2005; 46(7): 1164 - 1170. [Abstract] [Full Text] [PDF]

				M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]

				R. J. Robbins, S. Srivastava, A. Shaha, R. Ghossein, S. M. Larson, M. Fleisher, and R. M. Tuttle Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6010 - 6016. [Abstract] [Full Text] [PDF]

				F. Furuya, H. Shimura, A. Miyazaki, K. Taki, K. Ohta, K. Haraguchi, T. Onaya, T. Endo, and T. Kobayashi Adenovirus-Mediated Transfer of Thyroid Transcription Factor-1 Induces Radioiodide Organification and Retention in Thyroid Cancer Cells Endocrinology, November 1, 2004; 145(11): 5397 - 5405. [Abstract] [Full Text] [PDF]

				E. Mazzaferri A Randomized Trial of Remnant Ablation--In Search of an Impossible Dream? J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3662 - 3664. [Full Text] [PDF]

				M. Torlontano, M. Attard, U. Crocetti, S. Tumino, R. Bruno, G. Costante, G. D'Azzo, D. Meringolo, E. Ferretti, R. Sacco, et al. Follow-Up of Low Risk Patients with Papillary Thyroid Cancer: Role of Neck Ultrasonography in Detecting Lymph Node Metastases J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3402 - 3407. [Abstract] [Full Text] [PDF]

				C. E. Palme, Z. Waseem, S. N. Raza, S. Eski, P. Walfish, and J. L. Freeman Management and Outcome of Recurrent Well-Differentiated Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, July 1, 2004; 130(7): 819 - 824. [Abstract] [Full Text] [PDF]

				I. L. Wapnir, M. Goris, A. Yudd, O. Dohan, D. Adelman, K. Nowels, and N. Carrasco The Na+/I- Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid Clin. Cancer Res., July 1, 2004; 10(13): 4294 - 4302. [Abstract] [Full Text] [PDF]

				F. Furuya, H. Shimura, H. Suzuki, K. Taki, K. Ohta, K. Haraguchi, T. Onaya, T. Endo, and T. Kobayashi Histone Deacetylase Inhibitors Restore Radioiodide Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and Thyroglobulin Endocrinology, June 1, 2004; 145(6): 2865 - 2875. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri, R. J. Robbins, C. A. Spencer, L. E. Braverman, F. Pacini, L. Wartofsky, B. R. Haugen, S. I. Sherman, D. S. Cooper, G. D. Braunstein, et al. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1433 - 1441. [Abstract] [Full Text] [PDF]

				M. E. Spieth, S. B. Standiford, M. E. Starkman, and J. Gough Recombinant TSH-Stimulated, Radioguided Differentiated Thyroid Carcinoma Surgery Clin. Med. Res., January 1, 2003; 1(1): 53 - 56. [Abstract] [Full Text] [PDF]

				A. Stojadinovic, M. Shoup, A. Nissan, R. A. Ghossein, J. P. Shah, M. F. Brennan, and A. R. Shaha Recurrent Differentiated Thyroid Carcinoma: Biological Implications of Age, Method of Detection, and Site and Extent of Recurrence Ann. Surg. Oncol., October 1, 2002; 9(8): 789 - 798. [Abstract] [Full Text] [PDF]

				F. Pacini, E. Molinaro, F. Lippi, M. G. Castagna, L. Agate, C. Ceccarelli, D. Taddei, R. Elisei, M. Capezzone, and A. Pinchera Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5686 - 5690. [Abstract] [Full Text] [PDF]

				M. R. Castro, E. R. Bergert, J. R. Goellner, I. D. Hay, and J. C. Morris Immunohistochemical Analysis of Sodium Iodide Symporter Expression in Metastatic Differentiated Thyroid Cancer: Correlation with Radioiodine Uptake J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5627 - 5632. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				T. Ota, Y. Bando, M. Hirai, N. Tanaka, Y. Takabatake, Y. Kasahara, and M. Fujisawa Papillary Carcinoma of the Thyroid with Distant Metastases to the Cerebrum: a Case Report Jpn. J. Clin. Oncol., March 1, 2001; 31(3): 112 - 115. [Abstract] [Full Text] [PDF]

				Y. Nakamoto, T. Saga, T. Misaki, H. Kobayashi, N. Sato, T. Ishimori, S. Kosugi, H. Sakahara, and J. Konishi Establishment and Characterization of a Breast Cancer Cell Line Expressing Na+/I- Symporters for Radioiodide Concentrator Gene Therapy J. Nucl. Med., November 1, 2000; 41(11): 1898 - 1904. [Abstract] [Full Text] [PDF]

				F. de Vathaire, C. Hardiman, A. Shamsaldin, S. Campbell, E. Grimaud, M. Hawkins, M. Raquin, O. Oberlin, I. Diallo, J.-M. Zucker, et al. Thyroid Carcinomas After Irradiation for a First Cancer During Childhood Arch Intern Med, December 13, 1999; 159(22): 2713 - 2719. [Abstract] [Full Text] [PDF]

				Y. Kitamura, K. Shimizu, M. Nagahama, K. Sugino, O. Ozaki, T. Mimura, K. Ito, K. Ito, and S. Tanaka Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4043 - 4049. [Abstract] [Full Text]

				P. Fonseca Thyroid lung metastasis diagnosed 47 years after thyroidectomy Ann. Thorac. Surg., March 1, 1999; 67(3): 856 - 857. [Abstract] [Full Text] [PDF]

				L. Wartofsky Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4195 - 4199. [Full Text]

				C. A. Spencer, M. Takeuchi, M. Kazarosyan, C. C. Wang, R. B. Guttler, P. A. Singer, S. Fatemi, J. S. LoPresti, and J. T. Nicoloff Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1121 - 1127. [Abstract] [Full Text]